Introduction
Epidermal growth factor receptor (EGFR) is activated by several ligands, including amphiregulin (AR) (Shoyab et al., 1988; Johnson et al., 1993a) . This receptor and its ligands appear to play a very critical role in the pathogenesis and progression of breast cancer (Ethier, 1995) . The EGFR is detected in approximately 45% of breast cancers with a negative correlation with estrogen receptor (ER) expression. There is a relationship between high EGFR levels and poor prognostic markers such as lymph node involvement, poor tumor dierentiation, high histological grade, and increased cellular proliferation (review see Klijn et al., 1992) .
AR is a member of the EGF family, originally isolated from serum-free conditioned medium of the human breast carcinoma cell line MCF-7 treated with the tumor promoter phorbol 12-myristate-13-acetate (PMA) (Shoyab et al., 1988) . AR has 38% amino acid homology with EGF and 32% homology with TGFa. Its gene is located on the long arm of human chromosome 4 (4q13 ± 4q21) (Plowman et al., 1990) .
AR is commonly expressed by various normal and malignant human epithelial cells (Shoyab et al., 1988; Plowman et al., 1990) , and was shown to be an autocrine growth factor in normal and c-Ha-ras-or c-erbB-2-transformed mammary epithelial cells (Li et al., 1992; Normanno et al., 1994) and other transformed cells (Johnson et al., 1992) . Together with other EGF family growth factor members, it has been suggested that AR plays a major role in the morphogenesis and differentiation of the mouse mammary gland (Kenney et al., 1995) . AR accumulates in the gland of both nulliparous and parous mice, suggesting that these factors are positioned to contribute to abnormal development in the older mammary gland, predisposing them to tumorigenesis (Herrington et al., 1997) . AR protein expression is increased in mammary tumors developed in transgenic mouse strains overexpressing oncogenes such as TGFa, neu, int-3 (Kenney et al., 1996a) , suggesting a role for AR in the promotion and/or progressive stages of mouse mammary tumorigenesis (Kenney et al., 1996b) . In human breast cancers, immunoactive AR was detected in 35 ± 77% of in®ltrating breast carcinomas, and also in in situ carcinomas or adjacent non-involved breast tissues (LeJeune et al., 1993; Qi et al., 1994; Panico et al., 1996) .
We have successfully immortalized, using SV40 T antigen, normal human mammary epithelial cells. After successive passages in nude mice, a highly tumorigenic cell line was selected, NS2T2A1, in which we demonstrated an increased EGFR expression both in vitro and in vivo and a dramatic increase of AR expression. To investigate the functional role of AR in this malignant phenotype, NS2T2A1 cells were stably transfected with an antisense cDNA to AR. We demonstrate that a striking inhibition of AR expression in the NS2T2A1 cell line following AR antisense RNA expression reverses the malignant phenotype of this cell line. We also show that the reversion of the transformed phenotype in nude mice is accompanied by a reduction of tumor angiogenesis.
Results
Expression of EGFR and AR in the transformed human mammary epithelial NS2T2A1 cell line The NS2T2A1 cell line was established from normal human mammary epithelial cells in primary culture immortalized by SV40 T antigen (Berthon et al., 1992) . The immortalized cells were successfully passaged by s.c. injection in nude mice with increasing tumorigenicity (Lebeau et al., 1995) . EGFR and AR expression paralleled tumorigenicity in this experimental model (Ma et al., 1998) . Using two speci®c antibodies, the immunocytochemical analysis of the most tumorigenic cell line NS2T2A1 demonstrated a membrane protein expression of EGFR and a cytoplasmic-nuclear AR protein expression. Using dual staining, EGFR and AR were found co-expressed in 50 ± 60% cells; 30 ± 40% cells expressed the AR without EGFR expression and approximately 510% cells were not stained either with EGFR or AR antibody (Figure 1 ). These data suggest the existence of autocrine interactions mediated by EGFR and AR in the NS2T2A1 cell line and a putative role in its tumorigenic potential.
Isolation of AR antisense RNA expressing NS2T2A1 cells
To demonstrate a role for AR in the tumorigenicity of the NS2T2A1 cell line, AR expression was inhibited by antisense RNA. To obtain stable transfected clones, the Epstein Barr virus origin of replication and nuclear antigen were removed from the pCEP4 vector to obtain the pCEP 4M modi®ed vector. AR antisense RNA expressing vector (pCEP-AR) was constructed with a 1.1 kb AR cDNA fragment orientated in the 3' to 5' orientation, under the control of the CMV promotor, with the resistance gene to hygromycin B.
After transfection, cells were selected by hygromycin B and surviving isolated clones were collected. Total RNA obtained from the parental NS2T2A1 cells, pCEP 4M vector transfected control cells (NS2T2A1 V) and antisense RNA expressing vector transfected cells was hybridized to a 32 P-labeled AR sense riboprobe that protected a 230 base AR antisense RNA fragment in a RNase protection assay. Among 65 pCEP-AR transfected clones, three (AR AS1-3) were selected for positivity for AR antisense RNA expression (Figure 2 ).
AR expression is inhibited in AR AS cells
Since AR expression can be induced by EGF or insulin in several cell lines (Barnard et al., 1994; Silvy et al., 1998; Vardy et al., 1995) including the NS2T2A1 cell line (not shown), transfected cells were cultured in EGF-free medium containing 2% of carbon-dextran depleted fetal bovine serum and hygromycin B before study. Expression of the cell-associated AR precursor protein in the antisense RNA expressing cells was studied by Western blotting with the actin detection as internal control. The production of the 55 ± 60 kD AR protein was reduced to about 50% in AR AS1 and AR AS2 cells, and to 55% in AR AS3 cells when compared to NS2T2A1 V control cells (Figure 3 ). Therefore AR expression was variably inhibited in AR antisense expressing clones. In AR AS clones, the 230 base AR antisense RNA fragment was protected by an AR sense riboprobe. The 154 base GAPDH mRNA fragment was protected by a GAPDH antisense riboprobe as an internal control was inhibited to the greatest degree (55%) grew more slowly (doubling time of 36 h). (Figure 4 ).
The dierent cell lines were therefore tested for anchorage-independent growth (AIG) in soft agar. Clonogenicity of AR AS1, AR AS2 and AR AS3 cells was reduced respectively to 23.6, 32.4 and 6.8% of that observed for NS2T2A1 V cells. NS2T2A1 V control cells cultured in hygromycin B containing medium yielded 33% colony forming eciency relative to the non-transfected NS2T2A1 cells (Table 1) .
Inhibition of AR expression reverse the transformed phenotype of the NS2T2A1 cell line in vivo Since transformation is characterized both by AIG and tumor formation in nude mice, we then tested the tumor phenotype in vivo. Transfected cells (10 7 ) were injected s.c. in nude mice. Seven weeks later, the mice were sacri®ced, tumor volume and weight were measured. As shown in Figure 5 and Table 2 , AR antisense expression inhibited signi®cantly the transformed phenotype of the NS2T2A1 cell line in vivo. AR antisense expressing cells showed not only a lower tumor intake, but also an important reduction in tumor size and weight compared with control cells. The in vivo transformed phenotype was almost completely reversed in AR AS3 cells in which AR expression was reduced the most.
As the tumors derived from AR antisense expressing cells were too small to isolate protein for Western blot analysis, tumor AR expression was detected by immunohistochemistry. AR immunostaining was detected in almost all tumor cells in the tumors derived from NS2T2A1 and NS2T2A1 V cells. However, its expression was heterogeneous in the tumors derived from the three AR antisense expressing cell clones with only 30 ± 60% of tumor cells being positive for AR after 49 days in the absence of hygromycin B selection ( Figure 6 ).
A correlation exists between inhibition of AR expression, reduced tumor growth and reduced tumor angiogenesis
Because EGF and TGFa can promote angiogenesis (Schreiber et al., 1986) a possible role for AR in angiogenesis was evaluated in the tumors derived from AR antisense expressing cells after endothelial cell staining with a polyclonal anti-factor VIII-related antigen antibody. Representative peripheral nonnecrotic areas were analysed following image analysis with Matrox Inspector program. Intra-tumoral vascularization was found to be comparable for NS2T2A1 and NS2T2A1 V cells. The vascular surface of the tumors derived from AR AS1, AR Figure 3 Western blot analysis. Sub-con¯uent cells cultured with (for NS2T2A1 V and AR AS cells) or without (for NS2T2A1 cells) hygromycin B were lysed. Twenty-®ve mg reducing cell lysates were separated on 12% SDS ± PAGE and transferred to nitrocellulose ®lter which was then probed with polyclonal rabbit anti-AR antibody AR-Ab2 and anti-actin antibody (A). AR signal intensity was normalized to the intensity of actin protein after density measurement using NIH image 1.95 software. The AR expression level of NS2T2A1 V cells is given a value of 100% (B) Table 3 ). Therefore, these data suggest a positive eect of AR protein on tumor angiogenesis.
Discussion
The present study demonstrates the crucial role AR plays in the transformed phenotype as shown in an experimental model of tumorigenic transformed human mammary epithelial cells. This demonstration was made using stable transfection with an antisense RNA expressing vectors for AR. Moreover, it is suggested that part of the oncogenic properties of AR is related to its angiogenic capacity.
The co-expression of AR and EGFR was described in breast cancer cell lines (Plowman et al., 1990) and in EGFR positive primary breast cancers (LeJeune et Table 2 for tumor volume and weight evaluated at day 49). (SE: standard error) Figure 6 AR immunohistochemical study on cryostat sections prepared from tumors derived from NS2T2A1 (A), NS2T2A1 V (B) or AR AS1 cells (C). AR was detected using 605 antibody. Sections were counterstained with methyl green Figure 7 Immunohistochemical study for intra-tumoral vascularization. Cryostat sections were prepared from tumors derived from NS2T2A1 cells (A), NS2T2A1 V cells (B) or the AR AS1 cells (C). Intra-tumoral vascularization (in red) was detected using a rabbit polyclonal antibody directed against factor VIII-related antigen and a secondary anti-rabbit IgG conjugated to peroxidase. Sections were counterstained with hematoxylin , 1993) . These data already suggested the existence of an EGFR-AR autocrine loop in these tumors. In our experimental model, AR expression increased along with the tumorigenic potential and was paralleled by an increase of EGFR (not shown). The EGFR-AR co-expression was demonstrated by dual EGFR-AR immunostaining in the most tumorigenic NS2T2A1 cells which do not express estradiol receptors (Berthon et al., 1992) . Anti-EGFR antibodies and EGFR antisense RNA expression inhibited the transformed phenotype of NS2T2A1 cells (Ma et al., 1998) , as was shown previously in other breast cancer cell lines or human tumors in vivo (review see Modjtahedi and Dean, 1994) . AR is secreted as a monomer of either 81 or 87 amino acid residues after proteolytic cleavage of the 252 amino acid transmembrane precursor (Plowman et al., 1990; Shoyab et al., 1989; Thompson et al., 1996) , with a molecular weight ranging from 9.5 ± 60 kD, depending on the degree of glycosylation and NH2-terminal processing (Brown et al., 1998; Martinez-Lacaci et al., 1995 Johnson et al., 1993b; Shoyab et al., 1988) . In our NS2T2A1 cells, only the 55 ± 60 kD form of the AR was detected by Western blot analysis in the total protein lysate with the AR 605 polyclonal antibody. Speci®city was con®rmed by preabsorption with human recombinant AR. This 55 ± 60 kD AR isoform has been described as being the N-linked glycosylated form of the AR precursor, and like lower molecular AR, is able to activate the EGFR (Martinez-Lacaci et al., 1996) . AR protein expression is increased in mammary tumors developed in transgenic mouse strains overexpressing SV 40 T antigen (Kenney et al., 1996a) , and suggests a role for the promotion and/or progressive stages of mouse mammary tumorigenesis (Kenney et al., 1996b) . These ®ndings are consistent with our experimental human model, where normal human mammary epithelial cells were immortalized by SV 40 T antigen. Further selection of more tumorigenic cell variants led to NS2T2A1 cells with an increased AR expression. Various growth factors or cytokines have been described to regulate AR expression or protein secretion. Insulin, IGF-1 (Vardy et al., 1995) , EGF family growth factors (Barnard et al., 1994) , IL-1a, TNFa and IL-6 , as well as estradiol (Martinez-Lacaci et al., 1995 were described as potent stimulators of AR expression in cancer cell lines of various origin. Conversely, TGFb1 and 2 were described either as stimulators or inhibitors of AR secretion according to the cell lines tested (Bennett et al., 1992) .
In most instances AR functions as a mitogen, but can inhibit the growth of human cancer cells, depending upon the concentration used, the presence of other growth factors, and the nature of the cell lines (Cook et al., 1991; Johnson et al., 1991 Johnson et al., , 1992 Johnson et al., , 1993a Johnson et al., , 1994 Plowman et al., 1990; Shoyab et al., 1988; Thompson et al., 1996) . In vitro, antisense oligonucleotides against AR were reported to partially inhibit AR expression and anchorage-dependent growth of immortalized-nontransformed human mammary epithelial 184A1N4 cells (Kenney et al., 1993) and human pancreatic cancer T3M4 cells (Funatomi et al., 1997) . They also inhibited anchorage-independent growth of c-Ha-ras and c-erbB2 transformed human mammary epithelial MCF-10A cells and colon cancer GEO cells . This strategy although of great interest suers from variations linked to drug in¯ux variability and to extra-and intra-cellular interactions (aptamer) (Ma and Calvo, 1996) . We therefore chose a dierent strategy using antisense cDNA construct stable transfection. In the present study, AR antisense RNA expression could inhibit dramatically AR protein expression in NS2T2A1 cells. Although cellular anchorage-dependent growth in serum-containing medium was inhibited only when AR expression was reduced to 55%, a signi®cant inhibition of the anchorage-independent growth in vitro was achieved. In NS2T2A1 cells, another EGF family growth factor TGFa has been identi®ed. Using either antibodies or antisense oligonucleotides to TGFa we could not demonstrate such a dramatic reduction of clonogenicity in NS2T2A1 cells as observed with AR antisense cDNA transfection, suggesting that AR is a major component of the autocrine proliferation loop involving EGFR. The transformed phenotype in vivo of this highly aggressive NS2T2A1 cell line was reversed by blocking AR expression to about 50% or less level. This reduction of AR level was not associated with either the site numbers of membrane EGFR or the anity constant of the receptor as veri®ed by 125 I-EGF binding assay (not shown). This is the ®rst report demonstrating that AR expression is crucial for tumor formation (oncogenic property) and that a reduction in AR production is sucient to reverse tumor formation in vivo.
EGF and TGFa are potent angiogenic mediators (Schreiber et al., 1986) . TGFa was found to function as a potent inducer of vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) synthesis (Detmar et al., 1994) . A GC-rich TGFaresponsive region of the VPF/VEGF promoter has been identi®ed as necessary for TGFa-inducible transcriptional activation. Both AP-2 and Egr-1 transcription factors were detected as components of the TGFa-inducible protein complex (Gille et al., 1997) . A similar eect by AR has not been reported to date but may be involved in VPF/VEGF expression. In the present study, a signi®cant decrease of tumor vascular density was observed in the tumors derived from AR antisense RNA expressing cells, suggesting a role in the angiogenesis for AR. This role could be through a direct positive regulation mediated by AR or via an inhibitory factor produced when AR expression is decreased.
Altogether, the present data indicate the importance of AR in the transformed phenotype of the NS2T2A1 cell. Moreover, AR is shown to play a role in tumor angiogenesis. These ®ndings suggest that AR could represent a target for therapy and as a prognostic factor in breast cancer. The possible role of VPF/ VEGF and other angiogenic factors is currently under investigation. Because AR was recently discovered to be involved in a 2 -integrin (Solic and Davies, 1997) and matrix metalloproteinase-9 (Kondapaka et al., 1997) regulation, this growth factor may have a complementary role in metastatic promotion, being involved in all steps of tumor progression.
Materials and methods

Immunocytochemistry
The monoclonal antibody (mAb) against human EGFR 528 (IgG 2a ) was prepared from the hybridoma (ATCC, Rockville, MD, USA) derived ascites and quanti®ed by electrophoresis. The rabbit polyclonal antibody 605 was raised against 8 ± 26 residues of human AR sequence (Johnson et al., 1991) .
Cultured cells were plated in EGF-free DMEM/F12 (1/1) medium without calcium (Biological Industries, Kibbutz Beit Haemek, Israel) containing 2% of carbon-dextran depleted fetal bovine serum (FBS) and 4 mM glutamine into dispodiagnostic slides. The cells were ®xed with acetone/methanol (1/1) for 2 min and incubated with 10 mg/ml of each antibody at 48C overnight, then with a secondary appropriate antibody conjugated to alkaline phosphatase (Caltag Laboratories, South San Francisco, CA) or biotin (Boehringer Mannheim, Mannheim, Germany). The EGFR was detected using a Fast blue BB salt containing substrate (Cordell et al., 1984) . The AR was detected by streptABC kit (Dako, Glostrup, Denmark) and 3-amino-9-ethyl carbazole (Sigma, St. Louis, MO, USA). Cell nuclei were counterstained with methyl green. Omission of the primary antibodies resulted in negative staining. The preimmune serum (604) of 605 antibody was tested as another negative control for AR immunostaining.
For EGFR-AR dual immunocytochemical staining, the cells were ®rst stained for EGFR and then for AR.
RNA expressing vectors
From a pCEP 4 vector (Invitrogen Corporation, San Diego, CA, USA) the Epstein Barr virus origin of replication and nuclear antigen were deleted and terminal ends were linked to obtain a new 6.2 kb pCEP 4M vector. The 1.1 kb AR EcoRI cDNA fragment (Plowman et al., 1990) was cloned into a polylinker, and then was subcloned by linker insertion (AR cDNA BamHI ± XhoI) in the opposite orientation to the human cytomegalovirus (CMV) immediate-early gene promotor of the pCEP 4M vector to obtain pCEP-AR construct. This vector was used for cell transfection.
The AR cDNA EcoRI ± NaeI fragment was subcloned into the pGEM 4 vector (Promega, Madison, WI, USA) to obtain pGEM-AR construct in order to have the sense cDNA strands transcribed by the SP6 polymerase to provide riboprobes for RNase protection assay.
Cell culture, transfection
Immortalized NS2T2A1 cell line was maintained in DMEM/ F12 (1/1) medium without calcium supplemented with 4 mM glutamine, 10 mg/ml insulin, 5 mM hydrocortisone, 2 ng/ml EGF and 5% horse serum Ca 2+ -chelated by Chelex 100 (Sigma, St. Louis, MO, USA) in 7% CO 2 in air at 378C in a humidi®ed incubator (Berthon et al., 1992) .
Transfections of the NS2T2A1 cells were performed by calcium phosphate co-precipitation and 48 h later cells were selected with 30 mg/ml hygromycin B (Boehringer Mannheim, Mannheim, Germany). The isolated clones were collected with clone cylinders and expanded.
RNA analysis
Cellular RNA was isolated by the guanidine cesium chloride method (Davis et al., 1986) and stored at 7808C.
pGEM-AR vector was linearized with XbaI and EcoRI respectively to synthesize an AR sense riboprobe with SP6 polymerase to protect a 230 base AR antisense RNA fragment. Linearized pTRI-GAPDH-human antisense control vector (Ambion, Austin, TX) was digested with DdeI to synthesize a GAPDH antisense riboprobe with T7 polymerase to protect a 154 base GAPDH mRNA fragment. The probes were labeled with 800 Ci/mmol a-32 P UTP (Amersham Life Science, Buckinghamshire, UK) using MAXIscript in vitro transcription kit (Ambion, Austin, TX, USA). The probes were puri®ed by 5% acrylamide/8 M urea gel.
Ten mg cellular RNA were mixed with 3610 4 c.p.m. labeled probes to perform the RNase protection assay using the Hybspeed RPA kit as described by the manufacturer (Ambion, Austin, TX, USA). After electrophoresis in 5% acrylamide/8 M urea gels, autoradiographs were performed.
Western blot analysis
Cells grown to approximately 80% con¯uency were collected and homogenized in RIPA buer containing 50 mM TrisCl pH 8.0, 150 mM NaCl, 0.1% SDS, 1% nonidet P-40, 0.5% 7-deoxycholic acid, 1 mM phenylmethyl sulfonyl¯uoride, and 20 mg/ml aprotinin. Following incubation on ice for 30 min, the total lysates were centrifuged for 3 min at 300 g at 48C. Supernatants were quanti®ed using BCA protein assay reagent (Pierce, Rockford, IL, USA) then mixed with reducing Laemmli sample buer. Twenty-®ve mg protein were loaded on 12% SDS ± PAGE gel for AR detection. Proteins were then transferred to nitrocellulose ®lter, and nonspeci®c binding was blocked for 2 h at 378C by preincubating the blot in TBS containing 5% nonfat dried milk and 0.05% tween-20. The AR was detected using anity-puri®ed polyclonal rabbit anti-AR antibody ARAb2, directed against residues 26 ± 44 of AR (Johnson et al., 1992 (Johnson et al., , 1993b , (1 mg/ml) overnight at 48C. The blots were then incubated for 1 h with horseradish peroxidase conjugated Fab fragments of goat anti-rabbit IgG antibody (Vector, Burlingame, CA, USA), and proteins were visualized with ECL reagent (Amersham Life Science, Buckinghamshire, UK). To control the protein amount an anity-puri®ed polyclonal rabbit anti-actin antibody (Sigma, St. Louis, MO, USA) was used. AR signal intensity was normalized to the intensity of the constitutive expressed actin protein after density measurement using NIH image 1.95 software.
Anchorage-dependent growth assay 6610 5 cells were seeded in 25 cm 2¯a sks in EGF-free medium containing 2% of carbon-dextran depleted fetal bovine serum, 4 mM glutamine and 30 mg/ml hygromycin B for the transfected cells. Cell growth was evaluated every day in duplicate by number counting.
Anchorage-independent growth assay
Cells (2610 4 cells/well) were seeded in triplicate in 0.3% agar (Difco, Detroit, MI, USA) mixed with DMEM/F12 (1/1) medium supplemented with 10% fetal bovine serum, 4 mM glutamine and 30 mg/ml hygromycin B for the transfected cells. This suspension was layered onto 0.5 ml 0.8% agar in medium base layer in 24-multiwell cluster dishes. After 3 weeks, colonies greater than 50 cells were counted using an inverted microscopy.
In vivo tumorigenicity
Cells grown to approximately 80% con¯uency were harvested and 10 7 cells were suspended in 0.2 ml PBS and injected s.c. into right¯anks of 5-week-old female Swiss nu/nu mice (Ia Credo, L'Arbresle, France). The growing tumors were measured once a week with a caliper, and tumor volumes were calculated as p6(average diameter) 3 /6. Animals were sacri®ced 7 weeks after cell injection. The tumors were weighed then frozen and stored in liquid nitrogen.
Immunohistochemistry and intra-tumoral vascularization quanti®cation
Cryostat sections (5 mm) were prepared from frozen tumors and ®xed in cold acetone for 10 min, incubated for 20 min in 0.6% H 2 O 2 . AR was detected with the immunocytochemical method as mentioned above. For vascular detection, the sections were incubated for 30 min in 3% bovine serumalbumin and for 1 h with a rabbit polyclonal antibody directed against factor VIII-related antigen (Dako, Glostrup, Denmark) at 1 : 200 dilution, then for 1 h with horseradish peroxidase conjugated Fab fragments of goat anti-rabbit IgG antibody (Vector, Burlingame, CA, USA) and detected using 3-amino-9-ethyl carbazole.
For quanti®cation of intra-tumoral vascularization, acquisition of images was done with a tri-CCD camera (LH750 RC3, LHES electronique, Cergy-Pontoise, France) connected to a Zeiss Axioskop microscope (Oberkochen, Germany) using Photomat software (Microvision instrument). Digitized images were treated by Matrox Inspector software (Matrox Electronic System). After color transformation, stained vascular surfaces were quanti®ed per cellular ®eld. Three full representative and non-necrotic ®elds for each tumor were quanti®ed using a 206 objective. The sections were counterstained with hematoxylin.
Statistical analysis
The data were analysed using Student's t-test.
